Search: WFRF:(Eliasson Björn 1959) >
Glucose-lowering tr...
-
Ekström, NilsGothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
(author)
Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register
- Article/chapterEnglish2012
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/160883
-
https://gup.ub.gu.se/publication/160883URI
-
https://doi.org/10.1111/j.1463-1326.2012.01591.xDOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-177843URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Aims: To analyse clinical characteristics and treatment results in unselected type 2 diabetes mellitus (T2DM) patients, with non-pharmacological treatment as well as the most commonly used pharmacological glucose-lowering treatment regimens, in everyday clinical practice. Methods: In this population-based cross-sectional study, information was linked from the Swedish National Diabetes Register, Prescribed Drug Register and Patient Register. T2DM patients with non-pharmacological treatment and T2DM patients continuously using the 12 most common pharmacological treatment regimens were included in the study (n = 163121). Results: There were statistically significant differences in clinical characteristics between the groups. Patients with insulin-based treatment regimens had the longest duration of diabetes and more cardiovascular risk factors than the T2DM-population in general. The proportion of patients reaching HbA1c =7% varied between 70.1% (metformin) and 25.0% [premixed insulin (PMI) + SU) in patients with pharmacological treatment. 84.8% of the patients with non-pharmacological treatment reached target. Compared to patients on metformin, patients on other pharmacological treatments had a lower likelihood, with hazard ratios ranging from 0.58; 95% confidence interval (CI), 0.540.63 to 0.97;0.940.99, of having HbA1c =7% (adjusted for covariates). Patients on insulin-based treatments had the lowest likelihood, while non-pharmacological treatment was associated with an increased likelihood of having HbA1c =7%. Conclusion: This nation-wide study shows insufficiently reached treatment goals for haemoglobin A1c (HbA1c) in all treatment groups. Patients on insulin-based treatment regimens had the longest duration of diabetes, more cardiovascular risk factors and the highest proportions of patients not reaching HbA1c target.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Miftaraj, Mervete,1970
(author)
-
Svensson, A. M.
(author)
-
Andersson Sundell, Karolina,1978
(author)
-
Cederholm, JanUppsala universitet,Allmänmedicin och preventivmedicin(Swepub:uu)janceder
(author)
-
Zethelius, BjörnUppsala universitet,Geriatrik(Swepub:uu)bjorzeth
(author)
-
Gudbjörnsdottir, Soffia,1962Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine(Swepub:gu)xgudso
(author)
-
Eliasson, Björn,1959Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine(Swepub:gu)xelibj
(author)
-
Göteborgs universitetInstitutionen för medicin
(creator_code:org_t)
Related titles
-
In:Diabetes Obesity & Metabolism: Wiley14:8, s. 717-7261462-89021463-1326
Internet link
Find in a library
To the university's database